Iqirvo failed as a treatment for the fatty liver disease MASH, but the drug is now FDA approved in primary biliary cholangitis. An Intercept Pharmaceuticals drug already treats this rare liver disease and Gilead Sciences is poised to compete with its PBC drug approaching an FDA decision this summer.

The post Ipsen, Genfit Drug That Missed in MASH Wins FDA Approval in a Much Rarer Liver Disease appeared first on MedCity News.

The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.

The post Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases appeared first on MedCity News.

Acquiring CymaBay Therapeutics gives Gilead Sciences another drug for its liver disease portfolio. CymaBay’s molecule, seladelpar, is under FDA review for treating primary biliary cholangitis, a rare disease affecting the bile ducts of the liver.

The post Gilead’s $4.3B CymaBay Acquisition Adds Liver Disease Drug Under FDA Review appeared first on MedCity News.

Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.

The post Sanofi Commits $1.7B to Buy an Entire Company, But Wants Just a Single Drug appeared first on MedCity News.

Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.

The post After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout appeared first on MedCity News.

The FDA again rejected Intercept Pharmaceuticals’ application seeking accelerated approval for its NASH drug and asked for more data. Instead, the biotech will stop all work in that fatty liver disease and focus on drugs for other serious but rare liver conditions.

The post After Second FDA Rejection, Intercept Abandons NASH Drug and Restructures appeared first on MedCity News.

Ipsen drug Bylvay is now FDA approved for treating pruritus, or severe itching, which is a complication of the rare liver disease Alagille syndrome. The oral drug was previously approved for treating pruritus in another rare inherited liver disease called PFIC.

The post Ipsen Itching Drug Scratches Off a Second FDA Approval in Rare Liver Indication appeared first on MedCity News.

89bio reported its NASH drug candidate met the main endpoints of a mid-stage clinical trial. In addition to demonstrating efficacy and safety according to measures the FDA says are needed to support a regulatory submission, 89bio says the results also show its drug could offer a dosing edge over potential rivals.

The post NASH Drug Biotech 89bio Nails Phase 2 Goals; Next Up Is a Pivotal Clinical Trial appeared first on MedCity News.

Ochre Bio’s Series A financing will support development of RNA therapies for chronic liver disease. Longer term, the company aims to develop therapies that regenerate organs in patients, potentially avoiding the need for organ transplants.

The post RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease appeared first on MedCity News.

Liver disease remains the focus of Genfit, despite a high-profile clinical trial failure in the fatty liver disease NASH. The company is building out its pipeline by acquiring Versantis, a clinical-stage biotech whose most advanced drug candidate brings a novel approach to treating a deadly chronic liver disease complication that has no FDA-approved therapies.

The post Genfit spreads its bets in a rare liver disease with buyout of Phase 2-ready biotech appeared first on MedCity News.

Two years after the stinging FDA rejection of its drug for the fatty liver disease NASH, Intercept Pharmaceuticals has more safety and efficacy data from a pivotal study that could support resubmission of a new drug application. The biotech said it will meet with the FDA later this month.

The post After initial failure, Intercept Pharma feels new data can get NASH drug approval appeared first on MedCity News.

Satellite Bio has emerged from stealth with technology for bioengineering tissue to restore organ function. The regenerative medicine startup, based on research from MIT and Boston University, is backed by $110 million in financing.

The post Regenerative med biotech Satellite unveils tissue-based tech to restore organ function appeared first on MedCity News.

Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but is currently in Phase 3 testing in another liver disease, primary biliary cholangitis. Meanwhile, Genfit is adding an early-stage drug candidate to its own pipeline via a separate transaction.

The post Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease appeared first on MedCity News.

Rectify Pharmaceuticals is taking an approach to disease that led to a successful franchise of Vertex Pharmaceutical lung drugs and expanding it to more diseases in more organs in the body. The startup has launched with $100 million in financing.

The post Atlas Venture-incubated Rectify lands $100M to transport drug hunt to new grounds appeared first on MedCity News.

The Danville, Pennsylvania-based system plans to work with rabbittransit to help patients get to their appointments on time. Additionally, researchers from Geisinger and Regeneron Genetics Center recently found a gene variant that’s associated with a reduction in the risk for chronic liver disease.

The post Geisinger’s latest work: An upcoming patient transportation initiative and new insight on chronic liver disease appeared first on MedCity News.

Gilead just lost one candidate, Bristol-Myers has licensed another; the race for non-alcoholic fatty liver disease drugs continues, as many companies eye its potential for a blockbuster drug.

The post With $100 million buy, BMS targets “richest opportunity for blockbuster drugs” appeared first on MedCity News.

The post Swiss maker of pump for late stage liver disease complications raises $9.3M appeared first on MedCity News.

The post Could image mapping offer way to do noninvasive liver biopsies? appeared first on MedCity News.

The post Forget mood rings – check out the color of your pee to see what’s going on appeared first on MedCity News.

The post Could your hand soap give you liver disease? appeared first on MedCity News.

The post JNJ, BioCrossroads invest in Hoosier pharma startup at work on potential hepatitis B cure appeared first on MedCity News.